Tue, Mar 3, 2015, 5:10 AM EST - U.S. Markets open in 4 hrs 20 mins

Recent

% | $
Quotes you view appear here for quick access.

Pharmacyclics Inc. Message Board

  • waithamcross waithamcross Jun 4, 2012 1:43 PM Flag

    material update in amsterdamn mid june

    Pharmacyclics plans to issue a material update on the ibrutinib clinical development program and its results in a press release after the EHA oral presentations.
    Oral Presentation at EHA, Amsterdam, The Netherlands (June 14-17, 2012)
    Date/Time: Saturday, June 16, 2012; 8:00 AM – 8:15 AM CET
    Location: Elicium 1
    Abstract # 1970: The Bruton's Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) is Highly Active and Tolerable in Relapsed or Refractory and Treatment Naive Chronic Lymphocytic Leukemia Patients, Updated Results of a Phase Ib/II Study.
    Dr. Susan M. O'Brien et al. MD Anderson Cancer Center, Houston, Texas.
    Oral Presentation at EHA, Amsterdam, The Netherlands (June 14-17, 2012)
    Date/Time: Saturday, June 16, 2012; 8:15 AM – 8:30 AM CET
    Location: Elicium 1
    Abstract # 1590: Combination of the Bruton's tyrosine kinase inhibitor PCI-32765 with bendamustine/rituximab in patients with relapsed/refractory chronic lymphocytic leukemia: Interim results of a phase Ib/II study.
    Dr. Jennifer Brown et al. Dana-Farber Cancer Institute, Boston, Massachusetts.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
PCYC
221.29+5.36(+2.48%)Mar 2 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Aruba Networks, Inc.
NASDAQMon, Mar 2, 2015 4:00 PM EST
NXP Semiconductors NV
NASDAQMon, Mar 2, 2015 4:00 PM EST